Derivatization of fullerenes to polyhydroxylated fullerenes, i.e., fullerenols (FLU), dramatically decreases their toxicity and has been reported to enhance the solubility as well as cellular permeability. In this paper, we report synthesis of FLU as nanocarrier and subsequent chemical conjugation of Methotrexate (MTX) to FLU with a serum-stable and intracellularly hydrolysable ester bond between FLU and MTX. The conjugate was characterized for physiochemical attributes, micromeritics, drug-loading, and drug-release and evaluated for cancer cell-toxicity, cellular-uptake, hemocompatibility, protein binding, and pharmacokinetics. The developed hemocompatible FL-MTX offered lower protein binding vis-à-vis naïve drug and substantially higher drug loading. The conjugate offered pH-dependent release of 38.20 ± 1.19% at systemic pH and 85.67 ± 3.39% at the cancer cell pH. FLU-MTX-treated cells showed significant reduction in IC50 value vis-à-vis the cells treated with pure MTX. Analogously, the results from confocal scanning laser microscopy also confirmed the easy access of the dye-tagged FLU-MTX conjugate to the cell interiors. In pharmacokinetics, the AUC of MTX was enhanced by approx. 6.15 times and plasma half-life was enhanced by 2.45 times, after parenteral administration of single equivalent dose in rodents. FLU-MTX offered enhanced availability of drug to the biological system, meanwhile improved the cancer-cell cytotoxicity, sustained the effective plasma drug concentrations, and offered substantial compatibility to erythrocytes.
breast cancer hydroxylated fullerene chemotherapy drug delivery nanoparticle antifolate drug
This is a preview of subscription content, log in to check access.
University Grant Commission, New Delhi, India, is highly acknowledged for Rajeev Gandhi National Fellowship to Mr. Manish Kumar (F1-17.1/2014-15/RGNF-2014-15 ST-RAJ-73879/(SA-III/Website)). This work would have been impossible without the gift sample of MTX from M/s Ipca Laboratories, Mumbai, India. Their support for the academic cause is highly appreciated.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Mody KT, Mahony D, Zhang J, Cavallaro AS, Zhang B, Popat A, et al. Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune resposes to bovine viral diarrhoea virus E2 protein. Biomaterials. 2014;35:9972–83.CrossRefPubMedGoogle Scholar
Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23.CrossRefPubMedGoogle Scholar
Radic S, Nedumpully-Govindan P, Chen R, Salonen E, Brown JM, Ke PC, et al. Effect of fullerenol surface chemistry on nanoparticle binding-induced protein misfolding. Nano. 2014;6(14):8340–9.Google Scholar
Jia M, Li Y, Yang X, Huang Y, Wu H, Huang Y, et al. Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect. ACS Appl Mater Interfaces. 2014;6(14):11413–23.CrossRefPubMedGoogle Scholar
Das M, Datir SR, Singh RP, Jain S. Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic acid-multiwalled carbon nanotube conjugate. Mol Pharm. 2013;10(7):2543–57. https://doi.org/10.1021/mp300701e.CrossRefPubMedGoogle Scholar